Speeches by Craft.

“Will the right hon. Gentleman give way on that point?”

“I agree 100%. We could work out the lifetime cost of a parent being out of work to care for their child who should be in education or in a suitable school, or even the cost of a parent having to draw back from working a certain amount of hours or from reaching where they could go in their career because of the stress t…”

“That would be helpful, thank you. Moving on to more data-related questions, is there any data that you can share around the extent of inappropriate prescribing, which has come up repeatedly?”

“Would it be based on concerns being reported to regulators?”

“Are you confident that that data that you are able to collect from this method reflects the accurate situation on the ground?”

“You do not currently collect data around where the extent of wraparound care is taking place?”

“Are you taking action to address inappropriate prescribing? Is there more that could be done in this space?”

“That would be helpful. Is there more that regulators could do in this space, and what would be needed from the Government to support that?”

“Is there a gap, therefore, in the evidence base for this, as you are an evidence-led organisation?”

“Even if it is contraindicated for other health ramifications?”

“Would you consider including a contraindication for use on GLP‑1s below a minimum BMI? It seems like what you were saying is that could push more people to go towards the black market rather than—”

“What can take place in this space to stop people either getting medications that have potential adverse effects on them, because it is contraindicated for other conditions they have, or that are inappropriate, or accessing drugs that are completely illegal and do goodness knows what?”

“In your role in this space, do you have any measures of success regarding whether you are able to clamp down on inappropriate prescribing? Are there more regulations that you are looking to bring forward or where is your—”

“John, if I could turn now to wraparound care and NICE guidance on that, during our inquiry we have heard about the importance of wraparound care from those with lived experience and from myriad professionals. Do you have any insights you can share about where and the extent to which the standards are being met for qual…”

“What do you think is needed then? Is the regulation fine and sufficient in this space, or is there something different that needs to—”

“Is there a risk that if the UK online and offline markets are regulated people will then opt to go elsewhere? Does that cause concern for you?”

“What measures have you got in place to address whether or not the actions you are taking are successful?”

“Do you feel that there is a bit of a gap then that lots of people can fall through?”

“If you do not collect the data on it, where does responsibility lie for monitoring the quality of that wraparound care?”

“I am trying to get to the heart of whether you see that guidance being implemented when it comes to the wraparound care side of it. We obviously have data on the use of prescribing, but not necessarily on that holistic side. It sounds like at the moment you do not have data on whether that guidance is being adhered to.”